Price regulation and generic competition in the pharmaceutical market

European Journal of Health Economics

Volumn 7, Issue 3, 2006, Pages 208-214

  Dalen, Dag Morten ^a   Strøm, Steinar ^b   Haabeth, Tonje ^b  

^a BI NORWEGIAN BUSINESS SCHOOL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Demand for pharmaceuticals; Discrete choice; Evaluation of yardstick based price regulation; Monopolistic competition

Indexed keywords

CETIRIZINE; CITALOPRAM; ENALAPRIL; GENERIC DRUG; LISINOPRIL; LORATADINE; OMEPRAZOLE;

ARTICLE; COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; EVALUATION; MATHEMATICAL MODEL; NORWAY; PATENT; PRIORITY JOURNAL; PROSPECTIVE PRICING;

COMMERCE; COST CONTROL; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; LEGISLATION, DRUG; MODELS, ECONOMETRIC; NORWAY;

EID: 33750066296     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0357-y     Document Type: Article

References (15)

1. Berry ST (1994) Estimating discrete choice model of product differentiation. Rand J Econ 25: 242-262
2. Berry ST, Levinsohn J, Pakes A (1995) Automobile prices in market equilibrium. Econometrica 63: 841-890
3. Berndt ER, Pindyck RS, og Azolay P (2003) Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs. J Ind Econ 51:243-270
4. Brenkers R, Verboven F (2002) Liberalizing a distribution system the European car market. CEPR discussion papers no 3622
5. Caves RE, Whinston MD, Hurwitz MA (1991) Patent expiry and competition in the US phamaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1-48
6. Frank RG, Salkever DS (1997) Generic entry and the pricing of pharmaceuticals. J Econ Manage Strategy 75-90
7. Grabowski H, Vernon J (1992) Brand loyalty; entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 35
8. Hausman J, Leonard G, Zona D (1994) Competitive analysis with differentiated products. Ann Econ Stat 34: 159-180
9. Hellerstein J (1998) The importance of physician in the generic versus-trade name prescription decision. Rand J Econ 29: 109-136
10. Hudson J (2000) Generic take-up in the pharmaceutical market following patent expiry. A multicountry study. Int Rev Law Econ 20: 205-221
11. Nevo A (2000) Mergers with differentiated products: the case of the ready-to-eat cereal industry. Rand J Econ 31: 395-421
12. Pavknic N (2002) Do pharmaceutical prices respond to patient out-of-pocket expenses? Rand J Econ 33: 469-487
13. Razzolini T (2004) The Norwegian market for pharmaceuticals and the non-mandatory substitution reform of 2001: the case of enalapril. Memorandum 12/04. Oslo: Department of Economics, University of Oslo
14. Stern S, Trajtenberg M (1998) Empirical implications of physician authority in pharmaceutical decisionmaking. NBER working paper 6851
15. Winkelmann R (2004) Co-payments for prescription drugs and the demand for doctor visits-evidence from a natural experiment. Health Econ 13: 1081-1089